BI 456906
The Book of Peptides is not a clinic and not your doctor. We do not sell, prescribe, recommend, or personalize any compound, and no grade or ranking here is an endorsement. In the United States, most of these compounds are not FDA-approved and are sold for laboratory research only; a few are prescription drugs, and some are controlled substances or banned in sport. Possessing or administering an unapproved compound outside an authorized setting may be unlawful. Nothing here is a recommendation to buy, possess, or self-administer anything. Consult a licensed physician before any decision involving peptide use.
Survodutide is a once-weekly GLP-1/glucagon dual receptor agonist from Boehringer Ingelheim and Zealand, currently in late-stage trials for obesity and MASH. Phase 2 data showed roughly 19% body-weight loss at the highest dose over 46 weeks, which is genuinely strong, but it is not yet approved and all human data comes from company-run trials. It is one of the most-searched grey-market fat-loss compounds despite no regulatory sign-off.